Strategic Alliance Between China Resources Beijing Medical Device Supply Chain and AccuMedical to Shape the Future of PFA Technology

This is not only a simple agreement, but also an "early move" in AccuPulse's national layout in China. CEO Yin Jie stated at the ceremony: "This deep collaboration with CRRC is an important milestone for our efforts in the Northern China market." Strategy Director Zhang Chunyan and Channel Director Wang Wei pointed out that the two parties will integrate their advantageous resources to focus on developing the platform supply chain system in the three northeastern provinces. Through deep channel integration, cutting-edge medical technologies and products will be delivered more smoothly and stably to this vast land, igniting a new engine for regional medical development.

Previously, Li Hongwei, General Manager of China Resources (Beijing) Medical Device Supply Chain Management Co., Ltd., and Li Shuheng, Executive Vice General Manager, personally visited Suzhou to deeply explore AccuPulse Medical Technology Co., Ltd., a leading enterprise specializing in pulsed field ablation (PFA) technology for cardiac applications. During the visit, AccuPulse showcased its self-developed integrated PFA system solution — from pulse generators, ablation catheters to 3D mapping systems — demonstrating the hard power of Chinese enterprises in the global cardiac intervention field through full-chain innovative technologies.

As the core issue of this talk, PFA technology is becoming a disruptive force in the field of cardiac electrophysiology with its unique advantages:

AccuPulse Medical Technology Co.Ltd was founded in November 2020. It is a company focused on platform-based technological innovation in the field of cardiac electrophysiology. With pulsed field ablation (PFA) and innovative three-dimensional mapping technology at its core, the company has developed more than 10 product pipelines covering the entire process of diagnosis and treatment for arrhythmias such as atrial fibrillation and premature ventricular contractions.

In April 2023, AccuPulse's self-developed AccuPulse Cardiac Pulsed Field Ablation System successfully completed all clinical study enrollments, placing it among the world’s first-tier clinical research products for pulsed field technology. On April 29, 2025, AccuPulse Medical Technology Co., Ltd's self-developed PFA Cardiac Pulse Ablation System officially received approval from China's National Medical Products Administration (NMPA) and was launched in China! The approved AccuPulse Cardiac Pulsed Field Ablation System was validated by 17 electrophysiology experts across eight research centers in China, achieving a 100% immediate success rate during procedures.

CR Beijing Medical Device Supply Chain is a company that focuses on orthopedics, rehabilitation, and medical device supply chain services. It is committed to building a comprehensive operational platform for the trade and circulation of medical devices in the orthopedic sector. With a core focus on establishing compliant and trustworthy systems, the company utilizes information technology applications as tools, relies on supply chain management and services, and features supply chain finance and value-added services. It aims to become a practitioner and promoter of China's national medical device supply chain strategic reform!

CR Beijing Medical Device Supply Chain, relying on the group's strong industrial foundation, proposes a highly forward-looking strategic path:

Supply Chain Reuse:Efficiently migrate the mature nationwide distribution network, cold chain logistics system, and clinical service experience in the orthopedic field to the electrophysiology track.

Acceleration of Channel下沉:Leverage distribution capabilities covering 31 provinces to drive the rapid penetration of PFA technology into grassroots markets;

Deepening Clinical Value:Combined with terminal hospital resources, build a full ecological service chain of "technology promotion + doctor training + patient management";

Innovation Incubation Empowerment:Opening up the industrial resources of central enterprises to accelerate the R&D iteration and commercial transformation of AccuPulse products.